Weight loss in a pill? Eli Lilly just took a big step closer to making it happen.
Orforglipron is a drug similar to Ozempic but without the injection, making it more accessible.
The pill, poised to revolutionize the weight loss world, may be up for FDA approval in late 2025.
A daily pill to rival Ozempic is one step closer to hitting the market.
Pharmaceutical giant Eli Lilly saw its stock jump Thursday morning after announcing initial Phase 3 trial results on orforglipron, a highly anticipated medication for diabetes and weight loss.
The drug is in the same class of GLP-1 medications as Ozempic, Wegovy, Mounjaro, and Zepbound — weekly injections that upended the weight-loss industry — but in pill form.
Lilly's head of diabetes and obesity Patrik Jonsson recently told Business Insider that orforglipron will likely unlock a much wider market, bringing the benefits of groundbreaking weight-loss drugs to people who can't, or don't want to, use injections.
"Most importantly, when you look at the global need, we expect that there are more than one billion people across the globe that are suffering from obesity," Jonsson said. "There is no way that we can meet those demands with injectable treatments today."
Lilly is racing to bring the first pill version of a GLP-1 for weight loss to market against competitors like Novo Nordisk and Pfizer, whose prospects have not lived up to expectations.
Novo Nordisk's Rybelsus, a daily pill with the same properties as Ozempic, was FDA-approved for diabetes in 2019.
However, its weight loss results didn't stack up to other GLP-1 drugs in studies, and it's not straightforward to take; users need to fast before and for 30 minutes after taking the pill.
Pfizer's daily pill, danuglipron, was scrapped after one study participant developed liver problems and recovered after they stopped taking the drug.
If all goes well for Lilly, orforglipron could be up for FDA approval for weight management by the end of 2025, and for type 2 diabetes treatment in 2026.
In the topline results released today, adults with diabetes who took orforglipron for 40 weeks had significantly better blood sugar control than those who took a placebo, according to a press release from Lilly.
They also lost up to 16 pounds (about 7.6% of their body weight) on average while taking the highest dose, and hadn't plateaued by the end of the study, suggesting even more weight loss could be possible.
The study — one of seven trials planned — found orforglipron is just as safe as other GLP-1 drugs, with the similar side effects like diarrhea and nausea.
The company intends to release more data later this year, Lilly's CEO David A. Ricks said in the press release.
The big question is: will it be cheaper than Ozempic, Wegovy, Mounjaro, or Zepbound?
While Eli Lilly has been tight-lipped about list price, analysts say there's a good chance orforglipron could cost less than the $900 monthly list price of current drugs, since a pill is easier to produce and distribute.
Read the original article on Business Insider
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
Why Novo Nordisk Stock Imploded This Week
Key Points Novo Nordisk shares dropped after slashing full-year sales guidance, primarily due to weakening sales of its blockbuster GLP-1 drugs, Ozempic and Wegovy. Competition from "compounders" marketing tailored versions of GLP-1 treatments is putting pressure on drug sales. Despite short-term challenges, Novo stock trades at one of its lowest P/E ratios in the last 30 years. 10 stocks we like better than Novo Nordisk › Shares of Novo Nordisk (NYSE: NVO) are falling this week, down 33% as of 3:27 p.m. ET on Friday. The drop comes as the S&P 500 lost 2.4%, and the Nasdaq-100 lost 2.2%. The Danish pharmaceutical giant's stock was hit after it released disappointing earnings showing that sales of its blockbuster GLP-1 drugs remain weaker than hoped. Novo Nordisk disappoints Novo Nordisk was forced to cut guidance for its top-line sales, driven primarily by lagging sales of its GLP-1 drugs, Ozempic and Wegovy. The company says it now expects full-year sales growth of 8% to 14%, down significantly from its earlier range of 13% to 21%. Its guidance for operating profit was cut as well, from between 16% and 24% to between 10% and 16%. Wegovy and Ozempic have been absolute blockbusters for the company, propelling Novo to the most valuable company in Europe before competition from "compounders" -- companies that market their own tailor-made versions using its active ingredients -- impacted sales. Is this a buying opportunity? I think Novo does have significant issues it must overcome, but I think these fears are overblown. For long-term investors, this seems like a great time to buy in. The company's stock is trading at one of its lowest price-to-earnings ratios (P/E) in nearly 30 years and the lowest in at least five years. This seems like an opportunity to me. Should you invest $1,000 in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* Now, it's worth noting Stock Advisor's total average return is 1,036% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Johnny Rice has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Why Novo Nordisk Stock Imploded This Week was originally published by The Motley Fool
Yahoo
14 minutes ago
- Yahoo
This popular energy drink may accidentally contain alcohol—what parents need to know
A packaging error involving two well-known beverage brands has triggered a safety recall—and raised new concerns for parents who keep Celsius energy drinks in their homes. According to a press release from High Noon, some of its vodka seltzer was accidentally packaged in cans labeled as Celsius Astro Vibe Sparkling Blue Razz energy drinks. The mislabeled cans contain alcohol but were distributed under non-alcoholic branding, with no external indication that they include vodka. The error occurred when a shared packaging supplier mistakenly sent empty Celsius cans to High Noon, which then filled them with vodka seltzer. The affected cans were shipped out between July 21–23, 2025, and sold in Florida, Michigan, New York, Ohio, Oklahoma, South Carolina, Virginia, and Wisconsin. 'Consumption of the liquid in these cans will result in unintentional alcohol ingestion,' the press release stated. Related: 5 million backyard pools recalled after fatal child drownings—what parents need to know Why this matters to moms If you're pregnant, breastfeeding, or have teens or tweens in the house who may be grabbing a Celsius from the fridge, this recall matters. It's possible that a can meant to provide an energy boost might instead contain alcohol—with no visual clues besides the lid color and lot code. Although no injuries or illnesses have been reported so far, the FDA has been notified, and High Noon is urging anyone with the affected cans to avoid drinking them and dispose of them immediately. Unintentional alcohol consumption can have serious implications for developing babies, young children, and adolescents. According to the Centers for Disease Control and Prevention (CDC), 'There is no known safe amount of alcohol use during pregnancy or while trying to get pregnant.' How to check your cans Look carefully at both the lot number and the lid color of any Celsius Astro Vibe Sparkling Blue Razz cans in your home. Do not consume if your can has a silver lid and a lot code between: L CCB 02JL25 2:55 to L CCB 02JL25 3:11 Cans with a black lid or different lot codes are not part of the recall and are safe to consume. The affected cans may have come from High Noon Beach Variety Packs, but even individual Celsius cans could be impacted, so it's important to check all relevant products. If you find a can that matches the lot code and silver lid description, dispose of it and contact High Noon Consumer Relations for a refund at: consumerrelations@ Related: Popular nursery chair recalled for overheating hazard—here's what parents need to know What this says about food safety labeling Labeling errors like this are rare but not unheard of. According to the FDA, 'food mislabeling' is one of the most common reasons for product recalls in the U.S. A 2022 study on product recall trends found that undeclared ingredients or wrong product contents are leading causes for consumer safety alerts. For parents juggling busy routines and making quick grocery runs, it's a reminder that we deserve better transparency and safeguards—especially when the consequences could impact kids. What to do next If you've purchased a High Noon Beach Variety Pack or a Celsius Astro Vibe Sparkling Blue Razz can recently: Check the lot code and lid color immediately. Do not consume if the product matches the affected range. Email High Noon Consumer Relations at consumerrelations@ for instructions and refund details. You can also refer to the official High Noon press release for additional guidance: High Noon recall notice. Sources: High Noon announces recall of its vodka seltzer beach pack due to inclusion of CELSIUS® Astro Vibe energy drink cans. July 29, 2025. PR Newswire. About alcohol use in pregnancy. Accessed July 30, 2025. Centers for Disease Control and Prevention. FDA 101: Product recalls. May 11, 2023. U.S. Food and Drug Administration. Undeclared allergens are the leading cause of recalls in 2023. March 15, 2023. Trustwell Blog.
The Hill
an hour ago
- The Hill
Sam's Club freeze dried fruit recalled over possible Listeria contamination
A recall has been issued for a popular dried fruit snack sold at Sam's Club amid concerns that the packages may be contaminated with Listeria. The snack is Member's Mark Freeze Dried Fruit Variety Pack 15-count. The U.S. Food and Drug Administration announced the recall by Doehler Dry Ingredient Solutions LLC, in a press release Thursday, noting that no illnesses had been reported yet from the possible Listeria monocytogenes exposure. According to the Food and Drug Administration (FDA), the contamination was discovered by the company during 'internal testing of their products.' The potentially affected products were distributed between July 1-25 and were sold at Sam's Club stores across the U.S. The FDA is advising people not to consume the snack if they purchased it during that window of time. Listeria monocytogenes can cause serious and sometimes fatal infections in young children, elderly people, and those with weakened immune systems. Exposure among healthy people can lead to symptoms like fevers, nausea and abdominal pain. Health officials warn that listeria can result in miscarriages and stillbirths among pregnant women.
